Dr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University School of Medicine. He is an interventional cardiologist and holds a PhD in engineering. He is a professor in both the Department of Medicine and the Department of Engineering (by courtesy) at Stanford.

Dr. Fitzgerald has led or participated in more than 175 clinical trials, has published more than 550 manuscripts and book chapters, and lectures worldwide. Over the past two decades, he has trained more than 150 postdoctoral researchers in engineering and medicine. Most recently, Dr. Fitzgerald completed two years of study toward a master’s degree focused on machine learning and agentic principles supporting AI.

Dr. Fitzgerald has been a principal founder of 24 medical startups in the San Francisco Bay Area and has transitioned 17 of them to large medical device companies. He serves on several boards of directors and advises dozens of medical device startups, as well as multinational healthcare companies, on the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Dr. Fitzgerald was part of the founding team of LVP Capital, a venture firm focused on medical device and biotechnology startups in San Francisco. In 2010, he co-founded Triventures, an early-stage medical technology fund with offices in Palo Alto and Tel Aviv.